ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting

    Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis

    Peter M. Maloley1, Bryant R. England2, Harlan Sayles1, Geoffrey M. Thiele1, Michael J. Duryee3, Jeffrey Payne4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, 5Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

     Background/Purpose:  Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
  • Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients

    Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy

    Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
  • Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model

    Yoshikazu Ogawa1, Nobunori Takahashi2, Toshihisa Kojima2 and Naoki Ishiguro2, 1Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, 2Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…
  • Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting

    Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study

    Alistair Reid1,2,3, Michael D Wiese4, Robert Metcalf5, Mihir D Wechalekar6,7, Anita Lee8,9, Catherine Hill2,10,11, Cindy Hall8, Leah McWilliams5, Les Cleland8 and Susanna Proudman12, 1Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, 2Medicine, The University of Adelaide, Adelaide, Australia, 3Medicine, University of Wollongong, Wollongong, Australia, 4School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, 5Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, 6Royal Adelaide Hospital, Adelaide, Australia, 7Rheumatology, Flinders University, Adelaide, Australia, 8Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, 9Rheumatology, University of Adelaide, Adelaide, Australia, 10The Queen Elizabeth Hospital, Adelaide, Australia, 11Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 12Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia

    Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
  • Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting

    An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis

    Thierry Dervieux1, Laura Martinez Prat2, John Conklin1, Claudia Ibarra1, Michael Mahler2, Michael E Weinblatt3 and Joel Kremer4, 1Exagen Diagnostics, Inc., Vista, CA, 2Research and Development, Inova Diagnostics, San Diego, CA, 3Brigham and Women's Hospital, Boston, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
  • Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting

    Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women

    Xinyi Liu1, Cianna Leatherwood1, Sara K. Tedeschi1, Medha Barbhaiya2, Cameron Speyer1, Bing Lu3, Karen Costenbader1, Elizabeth Karlson1 and Jeffrey A. Sparks1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
  • Abstract Number: 2046 • 2018 ACR/ARHP Annual Meeting

    Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies

    Mandar Bawadekar1, Zihao Zheng2, Alan J. Bridges3,4, Michael A. Newton5 and Miriam A. Shelef1,4, 1Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 2Departments of Statistics, University of Wisconsin - Madison, Madison, WI, 3Medicine, University of Wisconsin - Madison, Madison, WI, 4William S. Middleton Memorial Veterans Hospital, Madison, WI, 5Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI

    Background/Purpose: Rheumatoid arthritis patients produce a variety of anti-citrullinated protein antibodies (ACPAs) as well as antibodies that bind homocitrullinated and malondialdehyde-acetaldehyde adducted proteins leading to…
  • Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons

    Corinne Kowal1, Carey Shive2,3, Elizabeth Zebrowski4,5, Lenche Kostadinova1,6, Brianna Fuller1,6, Elane Reyes2, Kelsey Rife4, Amy Hirsch4, Anita Compan4, Shyam Kottilil7, Yngve Falck-Ytter6,8, Leonard H. Calabrese9, Donald Anthony4,6,10,11 and Maya Mattar6,12, 1Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, 2Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, 3VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, 4Louis Stokes VA Medical Center, Cleveland, OH, 5Department of Medicine, Case Western Reserve University, Cleveland, OH, 6Case Western Reserve University, Cleveland, OH, 7IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, 8Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, 9Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, 10Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, 11VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, 12Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH

    Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
  • Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting

    The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients

    Emma de Moel1, Veerle Derksen1, LA Trouw1, Holger Bang2, R.J. Goekoop3, I Speyer4, TWJ Huizinga1, CF Allaart1, REM Toes1 and Diane van der Woude5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Haga Hospital, The Hague, Netherlands, 4Haaglanden Medical Center, The Hague, Netherlands, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
  • Abstract Number: 72 • 2017 ACR/ARHP Annual Meeting

    The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients

    Onno J. Arntz1, Bartijn C.H. Pieters1, Rogier Thurlings2, Peter M. van der Kraan3, F van den Hoogen2 and Fons A.J. van de Loo3, 1Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, 2Rheumatology, Radboudumc, Nijmegen, Netherlands, 3Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Tumor-necrosis factor (TNF)-α plays a key role in the pathophysiology of rheumatoid arthritis (RA) and membrane bound TNFα is sufficient to induce arthritis in…
  • Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting

    Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients

    Annelies Blanken1, Marian van Beers-Tas1, Marlies Meursinge Reynders1 and Dirkjan van Schaardenburg1,2, 1Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands

    Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
  • Abstract Number: 480 • 2017 ACR/ARHP Annual Meeting

    ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance

    Raul Castellanos-Moreira Sr.1, Virginia Ruiz-Esquide1, María José Gomara2, Sonia Cabrera-Villalba1, Sebastian C Rodriguez-Garcia1, Georgina Salvador3, Andrea Cuervo1, Julio Ramírez1, M. Victoria Hernández1, Juan Cañete1, Isabel Haro2 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, 3Hospital Universitario Mutua Terrassa, Barcelona, Spain

    Background/Purpose: Autoantibodies (RF or ACPA) are found in sera from patients with palindromic rheumatism (PR) but there are no studies analyzing the presence of Anti-carbamylated…
  • Abstract Number: 482 • 2017 ACR/ARHP Annual Meeting

    The Link between ACPA and Erosion Development: Is ACPA Sufficient? an Association Study in Clinically Suspect Arthralgia

    Robin M ten Brinck1, REM Toes2 and Annette H.M. van der Helm-van Mil1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) associate with more severe joint erosions in rheumatoid arthritis (RA), but the underlying mechanism is unclear. Recent in vitro and…
  • Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting

    Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis

    Keith Knapp1,2, Eric Mueller1,2 and Gary Craig1,2, 1Arthritis Northwest PLLC., Spokane, WA, 2Discus Analytics LLC., Spokane, WA

    Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
  • Abstract Number: 1376 • 2017 ACR/ARHP Annual Meeting

    Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital

    Lieve Van Hoovels1, Julie Jacobs1, Bert Vander Cruyssen2, Stefanie Van den Bremt1, Patrick Verschueren3 and Xavier Bossuyt4, 1Laboratory medicine, OLV Hospital, Aalst, Belgium, 2Rheumatology, OLV hospital, Aalst, Belgium, 3Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, 4Laboratory medicine, University Hospital Leuven, Leuven, Belgium

    Background/Purpose: The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology